R-flurbiprofen
information and resources from the National Cancer Institute
NCI Thesaurus | R-flurbiprofen
An orally active synthetic enantiomer of flurbiprofen. R-flurbiprofen activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase. NCI Thesaurus | R-flurbiprofen
An orally active synthetic enantiomer of flurbiprofen. R-flurbiprofen activates c-Jun N terminal kinase, increases AP-1 binding to DNA, and downregulates cyclin D1 expression, resulting in arrest of tumor cells in the G1 phase of the cell cycle and apoptosis. This agent also affects the expression of nuclear factor kappa B, a rapid response transcription factor that stimulates the immune response to tumor cells. R-flurbiprofen does not inhibit the enzyme cyclo-oxygenase.
|
|
|
|
news articles
With Flurizan In Phase III, Myriad Bringing In $130M Nov 4, 2005
BioWorld Online (subscription), Flurizan (R-flurbiprofen), is in a two-arm Phase III study evaluating 800 mild Alzheimer's disease patients randomized to receive 800 mg twice daily or placebo ...
|
|
